IPHA
Innate Pharma S.A.
NASDAQ · Healthcare · Biotechnology · FR
$2.09
−1.18%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$232.90M
MomentumView details →
1D Return
−1.18%
YTD Return
+18.29%
RSI (14)
49.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
Market Cap
$232.90M
RSI (14)
49.1
MomentumView details →
1D Return
−1.18%
YTD Return
+18.29%
SummaryUpdated Dec 1, 2025
Innate Pharma S.A. (NASDAQ:IPHA) is a French biotechnology company founded in 1999 and headquartered in Marseille, France. The company went public on NASDAQ in October 2019. Innate Pharma specializes in discovering, developing, and commercializing therapeutic antibodies primarily focused on oncology treatments, with a particular emphasis on leveraging the immune system to fight cancer through innovative approaches including natural killer (NK) cell engagers and antibody-drug conjugates.
Similar companies
Latest newsMore news →
Innate Pharma S.A. announced an equity raise of EUR 30 million.21d agoInnate Pharma S.A. announced a strategic partnership.21d agoInnate Pharma and Sobi announced a strategic partnership to license lacutamab for T-cell lymphoma, with Sobi receiving exclusive global commercialization rights and potential full development rights.26d ago